Breaking through Barriers: Critical Success Factors for Launching Products with Breakthrough Therapy Designation

The FDA’s Breakthrough Therapy Designation (BTD) expedites patient access to innovative new treatments. While speeding up these processes can get new drugs to patients in need faster than they normally would through standard tracks, limited clinical evidence at launch and a compressed launch timeline can present stumbling blocks and uncertainties for commercialization teams tackling launch strategy, planning and execution.

A differentiated product will contribute to broader adoption in the marketplace, but that is not the sole factor determining its success. Launch teams must understand that they can control and shape the product’s trajectory.

Download the white paper to learn more about the implications of launching BTD products and some critical success factors.

https://www.eversana.com/insights/breaking-through-barriers-critical-success-factors-for-launching-products-with-breakthrough-therapy-designation/